Similarly in Uttenthal et al.'s20 study, WT1A-tetramer+CD8+ T-cell responses were observed in 6/8 AML patients following five cycles of 3-weekly doses of WT1A peptide vaccination. Here, CD8A is linked to acute myeloid leukemia.